Company Description
Pulmatrix, Inc., a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States.
The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications.
It engages in developing PUR1800, a narrow spectrum kinase inhibitor completed Phase 1b clinical trials for the treatment of acute exacerbations in chronic obstructive pulmonary disease; PUR1900 for the treatment of allergic bronchopulmonary aspergillosis in patients with asthma and cystic fibrosis; and PUR3100, an iSPERSE formulation of dihydroergotamine which is in Phase 1 for the treatment of acute migraine.
It has a license agreement with RespiVert Ltd. for access to a portfolio of kinase inhibitor drug candidates.
The company was founded in 2003 and is headquartered in Bedford, Massachusetts.
| Country | United States |
| Founded | 2003 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 22 |
| CEO | Peter Ludlum |
Contact Details
Address: 36 Crosby Drive, Suite 100 Bedford, Massachusetts 01730 United States | |
| Phone | 781 357 2333 |
| Website | pulmatrix.com |
Stock Details
| Ticker Symbol | PULM |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001574235 |
| CUSIP Number | 74584P301 |
| ISIN Number | US74584P3010 |
| Employer ID | 46-1821392 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Peter Ludlum CMA, MBA | Interim Chief Executive Officer |
| Dr. Alexander M. Klibanov Ph.D. | Founder |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 13, 2024 | 8-K | Current Report |
| Nov 8, 2024 | ARS | Filing |
| Nov 8, 2024 | DEF 14A | Other definitive proxy statements |
| Nov 8, 2024 | 10-Q | Quarterly Report |
| Nov 8, 2024 | 8-K | Current Report |
| Oct 8, 2024 | 8-K | Current Report |
| Aug 13, 2024 | 10-Q | Quarterly Report |
| Aug 13, 2024 | 8-K | Current Report |
| Jul 19, 2024 | 8-K | Current Report |
| May 30, 2024 | EFFECT | Notice of Effectiveness |